Front-line Treatment with Gemcitabine, Paclitaxel and Doxorubicin for Patients with Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study

OBJECTIVES: To estimate the response rate to gemcitabine, paclitaxel, and doxorubicin in patients with advanced urothelial carcinoma, we conducted a phase II clinical trial. Patients with renal insufficiency cannot receive standard cisplatin-based chemotherapy for urothelial carcinoma, and carboplat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Urology
Main Authors: Siefker-Radtke, Arlene O., Campbell, Matthew T., Munsell, Mark F., Harris, Deborah R., Carolla, Robert L., Pagliaro, Lance C.
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4792756/
https://ncbi.nlm.nih.gov/pubmed/26723185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.urology.2015.12.007
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares